Vaxcyte, Inc. PCVX
63.89 USD +1.97 (+3.18%)
At closeNov 9, 2026, 4:46 AM EST
64.19 +0.30 +0.47%
Pre-market · Nov 9, 4:46 AM ET
61.14 Day range 65.26
41.44 52-week range 90.75
- YTD
- +38.47%
- 1 year
- +53.40%
News
benzinga.com Vaxcyte Q3 EPS $(1.99) Beats $(2.12) Estimate Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.12) by 6.13 percent. This is a 27.56 percent decrease over losses of $(1.56) per…
globenewswire.com Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar…
benzinga.com Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.
benzinga.com Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…' Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
benzinga.com A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.